New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The robotic surgery program has continually pushed the boundaries of medical technology
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Decision on EU marketing authorisation for this population expected by September 2024
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Subscribe To Our Newsletter & Stay Updated
